Plasma Aβ42/Aβ40 and p-tau181 predict long-term clinical progression in a cohort with amnestic mild cognitive impairment

Z Xiao, W Wu, X Ma, X Liang, J Lu, L Zheng… - Clinical …, 2022 - academic.oup.com
Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …
被引用次数：12 相关文章

Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment

Z Xiao, W Wu, X Ma, X Liang, J Lu… - Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …

Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment

Z Xiao, W Wu, X Ma, X Liang, J Lu, L Zheng… - Clinical …, 2022 - academic.oup.com
Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …

Plasma Aβ42/Aβ40 and p-tau 181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment.

Z Xiao, W Wu, X Ma, X Liang, J Lu, L Zheng… - Clinical …, 2022 - europepmc.org
Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …